SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. Fang, Q. Xu, Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics, Clinical and Translational Oncology, 2015, 17, 3, 173

    CrossRef

  2. 2
    S. Shor, B.A. Fadl-Alla, H.C. Pondenis, X. Zhang, K.L. Wycislo, S. Lezmi, T.M. Fan, Expression of Nociceptive Ligands in Canine Osteosarcoma, Journal of Veterinary Internal Medicine, 2015, 29, 1
  3. 3
    Soussan Irani, Ali Salajegheh, Robert Anthony Smith, Alfred King-Yin Lam, A review of the profile of endothelin axis in cancer and its management, Critical Reviews in Oncology/Hematology, 2014, 89, 2, 314

    CrossRef

  4. 4
    Daniel L. Suzman, Sosipatros A. Boikos, Michael A. Carducci, Bone-targeting agents in prostate cancer, Cancer and Metastasis Reviews, 2014, 33, 2-3, 619

    CrossRef

  5. 5
    Stavros Sfoungaristos, Stephen J Frank, Mordechai Duvdevani, Ofer N Gofrit, Vladimir Yutkin, Ran Katz, Dov Pode, Petros Perimenis, Contemporary pharmacotherapy for the prevention of skeletal complications in patients with prostate cancer, Expert Opinion on Pharmacotherapy, 2014, 15, 17, 2513

    CrossRef

  6. 6
    D. Lorente, J.S. De Bono, Molecular alterations and emerging targets in castration resistant prostate cancer, European Journal of Cancer, 2014, 50, 4, 753

    CrossRef

  7. 7
    Howard S. Smith, Robert L. Barkin, Painful Boney Metastases, American Journal of Therapeutics, 2014, 21, 2, 106

    CrossRef

  8. 8
    Xiyun Deng, Guangchun He, Junwen Liu, Feijun Luo, Xiaoning Peng, Shigang Tang, Zhiyong Gao, Qinlu Lin, Jill M. Keller, Tao Yang, Evan T. Keller, Recent advances in bone-targeted therapies of metastatic prostate cancer, Cancer Treatment Reviews, 2014, 40, 6, 730

    CrossRef

  9. 9
    Ali Aydin, Zekai Halici, Erol Akpinar, A. Murat Aksakal, Murat Saritemur, Muhammed Yayla, C. Semih Kunak, Elif Cadirci, H. Tarik Atmaca, S. Sena Karcioglu, What is the role of bosentan in healing of femur fractures in a rat model?, Journal of Bone and Mineral Metabolism, 2014,

    CrossRef

  10. 10
    F. Cognetti, A. Bagnato, N. Colombo, A. Savarese, G. Scambia, J. Sehouli, P. Wimberger, R. Sorio, P. Harter, E. Mari, S. McIntosh, F. Nathan, K. Pemberton, K. Baumann, A Phase II, randomized, double-blind study of zibotentan (ZD4054) in combination with carboplatin/paclitaxel versus placebo in combination with carboplatin/paclitaxel in patients with advanced ovarian cancer sensitive to platinum-based chemotherapy (AGO-OVAR 2.14), Gynecologic Oncology, 2013, 130, 1, 31

    CrossRef

  11. 11
    David I Quinn, Catherine M Tangen, Maha Hussain, Primo N Lara, Amir Goldkorn, Carol M Moinpour, Mark G Garzotto, Philip C Mack, Michael A Carducci, J Paul Monk, Przemyslaw W Twardowski, Peter J Van Veldhuizen, Neeraj Agarwal, Celestia S Higano, Nicholas J Vogelzang, Ian M Thompson, Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial, The Lancet Oncology, 2013, 14, 9, 893

    CrossRef

  12. 12
    Lan Coffman, Collin Mooney, Jaeyoung Lim, Shoumei Bai, Ines Silva, Yusong Gong, Kun Yang, Ronald J. Buckanovich, Endothelin receptor-A is required for the recruitment of antitumor T cells and modulates chemotherapy induction of cancer stem cells, Cancer Biology & Therapy, 2013, 14, 2, 184

    CrossRef

  13. 13
    Ning Shao, Yang Wang, Wen Yu Jiang, Di Qiao, Shi Ge Zhang, Ye Wu, Xiang Xiang Zhang, Jiu Ling Wang, Yi Ding, Ning Han Feng, Immunotherapy and endothelin receptor antagonists for treatment of castration-resistant prostate cancer, International Journal of Cancer, 2013, 133, 7
  14. 14
    J.-P. Durand, M. Karoubi, P. Anract, F. Goldwasser, Metástasis óseas: manejo multidisciplinario, conducta diagnóstica y terapéutica, EMC - Aparato Locomotor, 2013, 46, 1, 1

    CrossRef

  15. 15
    Isabel Heidegger, Petra Massoner, Iris E. Eder, Andreas Pircher, Renate Pichler, Friedrich Aigner, Jasmin Bektic, Wolfgang Horninger, Helmut Klocker, Novel therapeutic approaches for the treatment of castration-resistant prostate cancer, The Journal of Steroid Biochemistry and Molecular Biology, 2013, 138, 248

    CrossRef

  16. 16
    K Miller, J W Moul, M Gleave, K Fizazi, J B Nelson, T Morris, F E Nathan, S McIntosh, K Pemberton, C S Higano, Phase III, randomized, placebo-controlled study of once-daily oral zibotentan (ZD4054) in patients with non-metastatic castration-resistant prostate cancer, Prostate Cancer and Prostatic Diseases, 2013,

    CrossRef

  17. 17
    Stéphane Oudard, Progress in emerging therapies for advanced prostate cancer, Cancer Treatment Reviews, 2013, 39, 3, 275

    CrossRef

  18. 18
    D.A. Loblaw, C. Walker-Dilks, E. Winquist, S.J. Hotte, Systemic Therapy in Men with Metastatic Castration-resistant Prostate Cancer: A Systematic Review, Clinical Oncology, 2013, 25, 7, 406

    CrossRef

  19. 19
    Teresa Maria Santos Amaral, Daniela Macedo, Isabel Fernandes, Luis Costa, Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment, Prostate Cancer, 2012, 2012, 1

    CrossRef

  20. 20
    Xuan Huang, Cindy H Chau, William D Figg, Challenges to improved therapeutics for metastatic castrate resistant prostate cancer: from recent successes and failures, Journal of Hematology & Oncology, 2012, 5, 1, 35

    CrossRef

  21. 21
    Evan Y. Yu, Kurt Miller, Joel Nelson, Martin Gleave, Karim Fizazi, Judd W. Moul, Faith E. Nathan, Celestia S. Higano, Detection of Previously Unidentified Metastatic Disease as a Leading Cause of Screening Failure in a Phase III Trial of Zibotentan Versus Placebo in Patients with Nonmetastatic, Castration Resistant Prostate Cancer, The Journal of Urology, 2012, 188, 1, 103

    CrossRef

  22. 22
    Jacqueline A. Clarkson-Jones, Alison S.J. Kenyon, John Kemp, Eva M. Lenz, Stuart D. Oliver, Helen Swaisland, Disposition and metabolism of the specific endothelin A receptor antagonist zibotentan (ZD4054) in healthy volunteers, Xenobiotica, 2012, 42, 4, 363

    CrossRef

  23. 23
    Eric H. Rubin, D. Gary Gilliland, Drug development and clinical trials—the path to an approved cancer drug, Nature Reviews Clinical Oncology, 2012, 9, 4, 215

    CrossRef

  24. 24
    M. L. Huber, L. Haynes, C. Parker, P. Iversen, Interdisciplinary Critique of Sipuleucel-T as Immunotherapy in Castration-Resistant Prostate Cancer, JNCI Journal of the National Cancer Institute, 2012, 104, 4, 273

    CrossRef

  25. 25
    J.-P. Durand, M. Karoubi, P. Anract, F. Goldwasser, Métastases osseuses : prise en charge multidisciplinaire, approche diagnostique et thérapeutique, EMC - Appareil locomoteur, 2012, 7, 4, 1

    CrossRef

  26. 26
    Marco Petrillo, Giovanni Scambia, Gabriella Ferrandina, Novel targets for VEGF-independent anti-angiogenic drugs, Expert Opinion on Investigational Drugs, 2012, 21, 4, 451

    CrossRef

  27. 27
    Heather Payne, Amit Bahl, Malcolm Mason, Janis Troup, Johann De Bono, Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities, BJU International, 2012, 110, 5
  28. You have free access to this content28
    Joel B. Nelson, Karim Fizazi, Kurt Miller, Celestia Higano, Judd W. Moul, Hideyuki Akaza, Thomas Morris, Stuart McIntosh, Kristine Pemberton, Martin Gleave, Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone, Cancer, 2012, 118, 22
  29. 29
    Malgorzata Mackiewicz-Wysocka, Magdalena Pankowska, Piotr J Wysocki, Progress in the treatment of bone metastases in cancer patients, Expert Opinion on Investigational Drugs, 2012, 21, 6, 785

    CrossRef

  30. 30
    Jin Li, Yanfei Liu, Jun Qian, Lennie Wu, John Kemp, Masahiro Nii, Helen Tomkinson, Yunxia Zuo, Malcolm Ranson, Michiyuki Usami, Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumors, Cancer Chemotherapy and Pharmacology, 2012, 70, 1, 57

    CrossRef

  31. 31
    Niall M Corcoran, Martin E Gleave, Targeted therapy in prostate cancer, Histopathology, 2012, 60, 1
  32. 32
    Álvaro Pinto, María Merino, Pilar Zamora, Andrés Redondo, Beatriz Castelo, Enrique Espinosa, Targeting the endothelin axis in prostate carcinoma, Tumor Biology, 2012, 33, 2, 421

    CrossRef

  33. 33
    Karen A. Autio, Howard I. Scher, Michael J. Morris, Therapeutic Strategies for Bone Metastases and Their Clinical Sequelae in Prostate Cancer, Current Treatment Options in Oncology, 2012, 13, 2, 174

    CrossRef

  34. 34
    B. Molitor, C. Börgermann, Zweitlinientherapie beim kastrationsresistenten Prostatakarzinom (CRPC), Der Urologe, 2012, 51, 3, 357

    CrossRef

  35. 35
    Flaminia Coluzzi, Analgesics for Cancer Pain, 2012,

    CrossRef

  36. 36
    Christos Chouaid, Faith Nathan, Kristine Pemberton, Thomas Morris, A phase II, randomized, multicenter study to assess the efficacy, safety, and tolerability of zibotentan (ZD4054) in combination with pemetrexed in patients with advanced non-small cell lung cancer, Cancer Chemotherapy and Pharmacology, 2011, 67, 5, 1203

    CrossRef

  37. 37
    M. Merino, A. Pinto, R. González, E. Espinosa, Antiangiogenic agents and endothelin antagonists in advanced castration resistant prostate cancer, European Journal of Cancer, 2011, 47, 12, 1846

    CrossRef

  38. 38
    Justin Sturge, Matthew P. Caley, Jonathan Waxman, Bone metastasis in prostate cancer: emerging therapeutic strategies, Nature Reviews Clinical Oncology, 2011,

    CrossRef

  39. 39
    Sergio Bracarda, Christopher Logothetis, Cora N. Sternberg, Stéphane Oudard, Current and emerging treatment modalities for metastatic castration-resistant prostate cancer, BJU International, 2011, 107,
  40. 40
    Se Joong Kim, Sun Il Kim, Current Treatment Strategies for Castration-Resistant Prostate Cancer, Korean Journal of Urology, 2011, 52, 3, 157

    CrossRef

  41. 41
    Flaminia Coluzzi, Ilenia Mandatori, Consalvo Mattia, Emerging therapies in metastatic bone pain, Expert Opinion on Emerging Drugs, 2011, 16, 3, 441

    CrossRef

  42. 42
    Rong Wang, Roderick H. Dashwood, Endothelins and their receptors in cancer: Identification of therapeutic targets, Pharmacological Research, 2011, 63, 6, 519

    CrossRef

  43. 43
    Megan N. Thobe, Robert J. Clark, Russell O. Bainer, Sandip M. Prasad, Carrie W. Rinker-Schaeffer, From Prostate to Bone: Key Players in Prostate Cancer Bone Metastasis, Cancers, 2011, 3, 4, 478

    CrossRef

  44. 44
    Roger S. Kirby, John M. Fitzpatrick, IMPROVED SURVIVAL PROSPECTS FOR PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER, BJU International, 2011, 107, 5
  45. 45
    Himisha Beltran, Tomasz M. Beer, Michael A. Carducci, Johann de Bono, Martin Gleave, Maha Hussain, William K. Kelly, Fred Saad, Cora Sternberg, Scott T. Tagawa, Ian F. Tannock, New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety, European Urology, 2011, 60, 2, 279

    CrossRef

  46. 46
    Cora N. Sternberg, Novel treatments for castration-resistant prostate cancer, European Journal of Cancer, 2011, 47, S195

    CrossRef

  47. 47
    Raid Aljumaily, Paul Mathew, Optimal Management of Bone Metastases in Prostate Cancer, Current Oncology Reports, 2011, 13, 3, 222

    CrossRef

  48. 48
    Helen Tomkinson, John Kemp, Stuart Oliver, Helen Swaisland, Maria Taboada, Thomas Morris, Pharmacokinetics and tolerability of zibotentan (ZD4054) in subjects with hepatic or renal impairment: two open-label comparative studies, BMC Clinical Pharmacology, 2011, 11, 1, 3

    CrossRef

  49. 49
    Donald L. Trump, Heather Payne, Kurt Miller, Johann S. de Bono, Joe Stephenson, Howard A. Burris, Faith Nathan, Maria Taboada, Thomas Morris, Andreas Hubner, Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancer, The Prostate, 2011, 71, 12
  50. 50
    Suzanne J. Farley, Prostate cancer: A rocky road to overcoming castration resistance, Nature Reviews Urology, 2011, 8, 1, 1

    CrossRef

  51. You have free access to this content51
    A Bagnato, M Loizidou, BR Pflug, J Curwen, J Growcott, Role of the endothelin axis and its antagonists in the treatment of cancer, British Journal of Pharmacology, 2011, 163, 2
  52. 52
    Timothy A. Yap, Andrea Zivi, Aurelius Omlin, Johann S. de Bono, The changing therapeutic landscape of castration-resistant prostate cancer, Nature Reviews Clinical Oncology, 2011, 8, 10, 597

    CrossRef

  53. 53
    J.A. Clarkson-Jones, A.S.J. Kenyon, H.K. Tomkinson, The disposition and metabolism of zibotentan (ZD4054): an oral-specific endothelin A receptor antagonist in mice, rats and dogs, Xenobiotica, 2011, 41, 9, 784

    CrossRef

  54. 54
    Michael A Carducci, Daniel Keizman, Targeted Therapies for Castration-Resistant Prostate Cancer, 2011,

    CrossRef

  55. 55
    Tanya B Dorff, David I Quinn, Cabazitaxel in prostate cancer: stretching a string, The Lancet, 2010, 376, 9747, 1119

    CrossRef